Discovering and developing novel medicines for acute and chronic degenerative diseases

Cypralis is developing of a novel category of small molecule drugs that inhibit cyclophilins, a large family of proteins involved in many diseases. The company has IP on three distinct classes of small molecules that share potent inhibition of cyclophilins, span a wide range of molecular weights, solubility, specificity and PK properties. We use these compounds as tools to validate inhibition of cyclophilins as novel therapeutic approach to treat diseases and as starting points for specific medicinal chemistry programmes.

A first development project CC-4066 has completed Phase 1 clinical trials in the indication “prevention and treatment of acute kidney injury associated to major surgery”.